Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Steroid response after Descemet membrane endothelial keratoplasty
Author Affiliations & Notes
  • Daniel B. Zander
    Eye Center, Universitatsklinikum Freiburg, Freiburg, Baden-Württemberg, Germany
  • Jana Jiang
    Eye Center, Universitatsklinikum Freiburg, Freiburg, Baden-Württemberg, Germany
  • Anne-Marie S. Kladny
    Eye Center, Universitatsklinikum Freiburg, Freiburg, Baden-Württemberg, Germany
  • Thomas Reinhard
    Eye Center, Universitatsklinikum Freiburg, Freiburg, Baden-Württemberg, Germany
  • Katrin Wacker
    Eye Center, Universitatsklinikum Freiburg, Freiburg, Baden-Württemberg, Germany
  • Footnotes
    Commercial Relationships   Daniel Zander Oculus Optikgeräte GmbH, Code R (Recipient); Jana Jiang None; Anne-Marie Kladny None; Thomas Reinhard None; Katrin Wacker None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 1082. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Daniel B. Zander, Jana Jiang, Anne-Marie S. Kladny, Thomas Reinhard, Katrin Wacker; Steroid response after Descemet membrane endothelial keratoplasty. Invest. Ophthalmol. Vis. Sci. 2024;65(7):1082.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To quantify steroid response in participants receiving topical steroids after Descemet membrane endothelial keratoplasty (DMEK).

Methods : This secondary analysis of prospective cohort studies included participants undergoing DMEK with and without cataract surgery for Fuchs’ dystrophy. Participants with type 1 diabetes, glaucoma, connective tissue disease or previous ocular surgery except for uncomplicated cataract surgery were not included. All participants received optical and morphological assessment of disease severity and intraocular pressure (IOP) measurements before surgery and at least at one post-operative visit. Topical dexamethasone was administered four times per day and tapered monthly to one time per day. Steroid response was graded as no response, moderate (IOP 20-31 mmHg or increase of 6-15 mmHg) or high (IOP >31mmHg or increase >15mmHg) compared to median pre-operative IOP.

Results : 172 eyes of 132 participants with a median age of 68 years (interquartile range [IQR], 61-75) were included. 137 eyes (80%) underwent DMEK with cataract surgery and 35 eyes (20%) underwent DMEK only. Before DMEK median IOP was 14 mmHg (IQR, 12-16). At a median 12.6 months after DMEK (IQR, 10.7-14.4), 35 participants (27%) were moderate and 4 (3%) were high steroid responders. Maximum IOP was 15 mmHg (median; IQR, 13-17) for non-responders, 21 mmHg (IQR, 20-23) for moderate responders and 39 mmHg (IQR, 33-53) for high responders. Median increase was 2 mmHg (IQR, 0-3) for non-responders, 7 mmHg (IQR, 4.5-8.5) for moderate responders and 22 mmHg (IQR, 15-37) for high responders. IOP measurements met the criteria of steroid response after 4.6 months after DMEK (median; IQR, 0.9-11.9). During follow up, 4 (100%) high responders and 6 (17%) moderate responders were identified by the attending physician. There was no difference in steroid response between patients undergoing DMEK with and without cataract surgery.

Conclusions : Every fifth DMEK patient had an increase in IOP associated with topical steroid therapy when compared to baseline. While steroid response was mostly moderate, less than 20% were detected in clinical practice. Determining baseline IOP before surgeries with known postoperative steroid regimens might help to identify steroid response and to prevent potential long-term complications.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×